Health
Novel nasal spray reduces viral replication by up to 96%: according to COVID-19 challenge study – BioPharma-Reporter.com
Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The novel nasal spray, INNA-051, is being developed by Australian biotech Ena Respiratory. The company has published its animal study, led by Public Health Englands Deputy Director Professor Miles Carroll, on biomedical pre-publication research site medRxiv.
The researchers note that INNA-051 significantly reduced COVID-19 virus levels in the nose and throat. A nasal administration delivered once or twice a week could be used to prevent infection in at-risk populations and healthcare workers, s…
-
Noosa News18 hours agoPedestrian killed as he’s struck by car on highway in Bowenville, Queensland
-
Noosa News21 hours agoAustralian men charged with allegedly trafficking firearms after international kidnapping investigation
-
Business24 hours agoThematic ASX ETF investing ideas
-
Business24 hours agoHere’s the average Australian superannuation balance at age 70